Search research articles
Contact Us
Filters
Showing results (131-140 of 210) with videos related to
Page
of 21
Sort By:
The Oncologist
|
February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
Debu Tripathy, Adam Brufsky, Melody Cobleigh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
Nicole J McCarthy, Xiaowei Yang, Ilona R Linnoila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Sara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.
Cancers
|
October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Sandra M Swain, Harrison Macharia, Javier Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2020
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Sandra M Swain, Gong Tang, Heather Ann Brauer, et al.
Breast Cancer Research and Treatment
|
February 28, 2021
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
Peter A Kaufman, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2012
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
D Craig Allred, Stewart J Anderson, Soonmyung Paik, et al.
Breast Cancer Research and Treatment
|
October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
Paula R Pohlmann, Deena Graham, Tianmin Wu, et al.
Journal of Proteome Research
|
February 9, 2008
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
Julia D Wulfkuhle, Runa Speer, Mariaelena Pierobon, et al.
Clinical Pharmacology and Therapeutics
|
January 31, 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Teresa T Ho, D Max Smith, Christina L Aquilante, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 210) with videos related to
Sort By:
Page
of 21
The Oncologist
|
February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
Debu Tripathy, Adam Brufsky, Melody Cobleigh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
Nicole J McCarthy, Xiaowei Yang, Ilona R Linnoila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Sara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.
Cancers
|
October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Sandra M Swain, Harrison Macharia, Javier Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2020
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Sandra M Swain, Gong Tang, Heather Ann Brauer, et al.
Breast Cancer Research and Treatment
|
February 28, 2021
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
Peter A Kaufman, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2012
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
D Craig Allred, Stewart J Anderson, Soonmyung Paik, et al.
Breast Cancer Research and Treatment
|
October 24, 2022
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
Paula R Pohlmann, Deena Graham, Tianmin Wu, et al.
Journal of Proteome Research
|
February 9, 2008
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
Julia D Wulfkuhle, Runa Speer, Mariaelena Pierobon, et al.
Clinical Pharmacology and Therapeutics
|
January 31, 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Teresa T Ho, D Max Smith, Christina L Aquilante, et al.
Page
of 21